跳至主要内容
临床试验/NCT01796925
NCT01796925已完成不适用

Clinical Study of the aura6000™ Targeted Hypoglossal Implantable Neurostimulation (THN) Sleep Therapy System

ImThera Medical, Inc.18 个研究点 分布在 5 个国家目标入组 57 人开始时间: 2013年2月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
57
试验地点
18
主要终点
Reduction in Oxygen Desaturation Index (ODI)

研究概览

简要总结

The objective of the study is to confirm the safety and efficacy in patients utilizing the aura6000 System for the treatment of Obstructive Sleep Apnea (OSA).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Noncompliant to CPAP
  • Willing to provide informed consent
  • Willing to comply with all follow-up visits and evaluations

排除标准

  • BMI limits
  • Central Sleep Apnea
  • Anatomic variations interfering with device placement or stability.

研究组 & 干预措施

aura6000 THN Therapy

Experimental

The aura6000 THN system will be implanted and activated for nightly therapy during sleep.

干预措施: aura6000 THN System (Device)

结局指标

主要结局

Reduction in Oxygen Desaturation Index (ODI)

时间窗: 3, 6, and 12 months post implant

Change from baseline in ODI measured through in-lab polysomnography (PSG).

Reduction in Apnea-Hypopnea Index (AHI)

时间窗: 3, 6, and 12 months post implant

Change from baseline in AHI measured through in-lab polysomnography (PSG).

Freedom from Serious Adverse Events (SAE)

时间窗: 1 and 12 months post implant

Adverse events and Serious Adverse events post-operatively

次要结局

  • Improvement in ESS(3, 6, and 12 months post implant)
  • Improvement in sleep fragmentation(3, 6, and 12 months post-implant)
  • Improvement in SAQLI(3, 6, and 12 months post implant)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (18)

Loading locations...

相似试验